MammoSite Brachytherapy Catheter Faces Reimbursement Difficulties
This article was originally published in The Gray Sheet
Executive Summary
Temporary codes denoting Proxima Therapeutics' MammoSite high-dose rate brachytherapy catheter are necessary to allow sufficient reimbursement of the technology under the hospital OPPS, according to the Pinnacle Health Group (PHG)
You may also be interested in...
OPPS Data To Improve? Hospitals Join Device Groups In Supporting “C” Codes
The American Hospital Association and the Federation of American Hospitals are withdrawing opposition to "C" codes for device tracking, acknowledging potential quality improvements to data used to set payment rates under the hospital outpatient system
OPPS Data To Improve? Hospitals Join Device Groups In Supporting “C” Codes
The American Hospital Association and the Federation of American Hospitals are withdrawing opposition to "C" codes for device tracking, acknowledging potential quality improvements to data used to set payment rates under the hospital outpatient system
Proxima, Laserscope, Medtronic Qualify For Improved Outpatient Payments
Adoption of Proxima Therapeutics' MammoSite high-dose rate brachytherapy catheter for early-stage breast cancer will increase with its placement into a new-technology APC, the firm maintains